证券代码：002872 证券简称：ST 天圣 公告编号：2025-070 天圣制药集团股份有限公司 关于公司控股股东部分股份被冻结的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 天圣制药集团股份有限公司（以下简称"公司"）于近日通过中国证券登 记结算有限责任公司系统查询到公司控股股东刘群先生所持公司部分股份被司 法冻结，现将有关事项公告如下： 一、股东股份被冻结的基本情况 | 股东 名称 | 是否为控 股股东或 第一大股 | 本次冻结 股份数量 | 占其所持 股份比例 | 占公司总 股本比例 | 是否为限 售股及限 | 起始日 | | 到期日 | 冻结申 请人 | 原因 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 东及其一 | （股） | | | 售类型 | | | | | | | | 致行动人 | | | | | | | | | | | 刘群 | | | | | 是,首发前 | 年 2025 | 2028 | 年 | 重庆市 第一中 | 司法 | ...

Core Viewpoint - The company has announced a change in its signing accountant for the 2025 annual audit, appointing Liu Wei to replace Yang Siqi due to the latter's work adjustment [1][3]. Group 1: Change of Signing Accountant - The company has retained Beijing Xinghua Accounting Firm for the 2025 financial statement and internal control audit [1]. - Liu Wei has been appointed as the new signing accountant, bringing experience from his work with listed companies since 2022 [3]. - The transition of responsibilities has been orderly, ensuring no adverse impact on the audit work for the 2025 financial statements [4]. Group 2: Risk Warning and Regulatory Actions - The company's stock has been under other risk warnings since June 5, 2019, due to allegations against the controlling shareholder for misappropriating company funds [6][7]. - The company received administrative penalty notices from the Chongqing Securities Regulatory Bureau on September 12 and November 7, 2025, related to false disclosures in financial reports [8]. - The controlling shareholder, Liu Qun, was found to have misappropriated a total of 125,074,926 yuan, which has been fully repaid as of April 8, 2021 [10].

证券代码：002872 证券简称：ST 天圣 公告编号：2025-068 天圣制药集团股份有限公司 关于变更签字会计师的公告 1 公司审计经验，具备相应专业胜任能力。 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 天圣制药集团股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日召 开的第六届董事会第十一次会议、第六届监事会第七次会议及 2025 年 5 月 23 日召开的 2024 年度股东大会审议通过了《关于续聘公司 2025 年度审计机构的 议案》，同意继续聘请北京兴华会计师事务所（特殊普通合伙）（以下简称 "北京兴华"）为公司 2025 年度财务报表和内部控制审计机构。具体内容详见 公司于 2025 年 04 月 29 日披露的《关于续聘公司 2025 年度审计机构的公告》 （公告编号：2025-029）。 公司于近日收到北京兴华出具的《关于变更天圣制药集团股份有限公司 2025 年度审计签字注册会计师的告知函》，现将具体情况公告如下： 一、签字会计师变更情况 北京兴华作为公司 2025 年度财务报表和内部控制的审计机构，原指派陈敬 波先 ...

证券代码：002872 证券简称：ST 天圣 公告编号：2025-069 天圣制药集团股份有限公司 关于公司股票交易被实行其他风险警示 相关事项的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、因控股股东涉嫌侵占公司资金触发其他风险警示，根据《深圳证券交易 所股票上市规则》相关规定，天圣制药集团股份有限公司（以下简称"公司" 或"天圣制药"）股票交易自 2019 年 6 月 5 日起被实施其他风险警示。 2、公司分别于 2025 年 9 月 12 日、2025 年 11 月 7 日收到了中国证券监督 管理委员会重庆监管局（以下简称"重庆证监局"）出具的《行政处罚事先告 知书》（处罚字（2025）4 号）、《行政处罚决定书》（（2025）4 号）。根据 《深圳证券交易所股票上市规则》第 9.8.1 条第（八）项规定，公司股票交易自 2025 年 9 月 15 日起被叠加实施其他风险警示。 一、实施其他风险警示的主要原因 1、控股股东刘群涉嫌侵占公司资金，由于刘群部分涉案财物已扣押、冻结、 查封，预计无法在一个月内将占用公司的资金归还。根 ...

Core Viewpoint - The company Tian Sheng Pharmaceutical has been found guilty of financial misconduct, including inflating profits and failing to disclose related party transactions, leading to a formal administrative penalty from regulators [1][2]. Group 1: Regulatory Actions - On November 8, Tian Sheng Pharmaceutical announced receipt of an administrative penalty decision from regulators, confirming violations in their 2017 and 2018 annual reports [1][2]. - The company is currently facing legal actions, with a case submitted to the court by a law firm representing affected investors [1]. Group 2: Violations Identified - The company inflated profits by approximately 120 million yuan over the years 2017 and 2018 through various means, including misappropriating funds from a subsidiary and inflating procurement costs [2][3]. - There were significant omissions in the annual reports regarding related party transactions, particularly concerning the company's control over certain entities [2][3]. Group 3: Investor Compensation - Affected investors who purchased shares between April 23, 2018, and January 8, 2025, and sold or still hold shares after January 9, 2025, are eligible to join the compensation claims [3]. - Investors are advised to prepare relevant transaction documents for the legal team to assess eligibility for claims [3].

Core Viewpoint - The article discusses the ongoing strict regulatory environment for listed companies in China, highlighting recent administrative penalties and investigations against several A-share companies, particularly focusing on issues related to financial misconduct and information disclosure violations [3][4]. Group 1: Regulatory Actions - Multiple A-share companies, including Longbai Group, Dongjiang Environmental Protection, and *ST Chuangxing, have received administrative penalties for various violations, including false financial reporting and undisclosed related-party transactions [3][5]. - Over 10 A-share companies have been penalized or investigated in November alone, with a significant number being ST companies, indicating a heightened regulatory scrutiny [3][4]. Group 2: Specific Cases - Longbai Group's subsidiary was fined 1.49 million yuan due to a safety incident that resulted in casualties and economic losses, while Dongjiang's subsidiary faced penalties for tax evasion amounting to 202.42 million yuan [6][7]. - *ST Chuangxing was found to have false financial records and inadequate disclosure of related-party transactions, leading to a correction order from the Shanghai Securities Regulatory Bureau and warnings issued to its executives [8][9]. Group 3: Other Companies Involved - Companies like Haosai and Jushihua were also investigated for information disclosure violations, with their stock prices dropping significantly following the announcements [10]. - Jia Ying Pharmaceutical faced penalties for failing to disclose 220 million yuan in related-party loans, resulting in warnings and fines totaling 4.9 million yuan [10][11]. - Hengli Tui, which has been delisted, was penalized for financial fraud involving inflated revenue figures, leading to fines of 39.4 million yuan against the company and its executives [13][14].

证券代码：002872 证券简称：ST 天圣 公告编号：2025-067 天圣制药集团股份有限公司 关于公司股票交易被实行其他风险警示 相关事项的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、因控股股东涉嫌侵占公司资金触发其他风险警示，根据《深圳证券交易 所股票上市规则》相关规定，天圣制药集团股份有限公司（以下简称"公司" 或"天圣制药"）股票交易自 2019 年 6 月 5 日起被实施其他风险警示。 2、公司分别于 2025 年 9 月 12 日、2025 年 11 月 7 日收到了中国证券监督 管理委员会重庆监管局（以下简称"重庆证监局"）出具的《行政处罚事先告 知书》（处罚字（2025）4 号）、《行政处罚决定书》（（2025）4 号）。根据 《深圳证券交易所股票上市规则》第 9.8.1 条第（八）项规定，公司股票交易自 2025 年 9 月 15 日起被叠加实施其他风险警示。 一、实施其他风险警示的主要原因 公司于 2025 年 4 月 29 日披露了《会计师事务所对非标意见涉及事项专项 说明》。北京兴华会计师事务所（特殊普 ...

Core Viewpoint - The article highlights the ongoing stringent regulatory environment in the A-share market, with multiple companies facing investigations and penalties for violations related to information disclosure and financial misconduct [2][10]. Group 1: Companies Under Investigation - Eight companies disclosed that they or their controlling shareholders and executives are under investigation by the China Securities Regulatory Commission (CSRC) for violations such as information disclosure and insider trading [2][3]. - Specific companies involved include Bayi Steel, Delisted Haiyue, Intercontinental Oil & Gas, Shanghai Washba, and *ST Changyao, with allegations ranging from information disclosure violations to false financial reporting [3][4]. Group 2: Administrative Penalties - Three companies, including Delisted Longyu, ST Tiantian, and *ST Jintai, received administrative penalties, with Delisted Longyu facing fines exceeding 30 million yuan for years of financial fraud [6][8]. - Delisted Longyu was found to have inflated revenue by approximately 14.54 billion yuan and profits by 37.32 million yuan through fictitious trading activities from 2019 to 2022 [6][7]. Group 3: Impact on Companies - Companies such as Intercontinental Oil & Gas and Shanghai Washba stated that the investigations would not adversely affect their operations, as the inquiries pertain to individual shareholders rather than the companies themselves [5]. - However, *ST Changyao warned that if the CSRC's findings lead to administrative penalties, it could trigger mandatory delisting due to serious violations [5]. Group 4: Broader Regulatory Trends - The article notes a trend of increasing accountability for companies that have been delisted, emphasizing that delisting does not exempt them from regulatory scrutiny [10]. - Recent cases show that even companies that have been delisted for over a year continue to face investigations and penalties for past violations [10][11].

Core Viewpoint - The article highlights the ongoing strict regulatory environment in the A-share market, with multiple companies facing investigations and penalties for violations related to information disclosure and financial misconduct [3][11]. Group 1: Regulatory Actions - Eight listed companies disclosed investigations or penalties from the China Securities Regulatory Commission (CSRC) for violations such as information disclosure and insider trading [3][5]. - Companies involved include Bayi Steel, Delisted Haiyue, and ST Changyao, with specific allegations ranging from financial data falsification to insider trading [5][6]. - The regulatory stance emphasizes that delisting does not exempt companies from accountability, marking a shift in enforcement where violations will be pursued relentlessly [3][11]. Group 2: Specific Cases of Investigation - Bayi Steel and ST Changyao are under investigation for information disclosure violations and false financial reporting, respectively [5][6]. - Delisted Haiyue's controlling shareholder is being investigated for information disclosure violations, while Intercontinental Oil and Shanghai Xiba are facing scrutiny for short-term trading and shareholder trading violations [5][6]. - Companies like Intercontinental Oil claim that the investigations do not impact their operations, asserting normal business continuity [6]. Group 3: Administrative Penalties - Three companies, including Delisted Longyu, ST Tian Sheng, and ST Jintai, received administrative penalties, with Delisted Longyu facing significant fines for years of financial fraud [7][8]. - Delisted Longyu was found to have inflated revenue by approximately 14.54 billion yuan and profits by 37.32 million yuan through fictitious trading activities from 2019 to 2022 [9]. - ST Jintai and ST Tian Sheng also faced penalties for failing to disclose annual reports on time and for profit inflation in previous financial statements [10][12]. Group 4: Broader Implications - The article notes that even companies that have been delisted are not escaping penalties, with several facing investigations for past violations [11][12]. - Recent statistics indicate that multiple companies have been penalized for failing to disclose annual reports or for falsifying financial data, reflecting a broader trend of increased regulatory scrutiny in the market [14][15].

Core Viewpoint - ST Tian Sheng Pharmaceutical Group Co., Ltd. and its controlling shareholder Liu Qun received an administrative penalty from the China Securities Regulatory Commission for financial misconduct, including inflated profits in annual reports for 2017 and 2018 [1] Financial Misconduct - In 2017, ST Tian Sheng inflated its total profit by 92,204,254.47 yuan, which accounted for 30.21% of the reported profit for that year [1] - In 2018, the inflated profit was 28,823,001.51 yuan, representing 20.61% of the reported profit for that year [1] - The company failed to timely disclose related party transactions, leading to significant omissions in the annual reports for both years [1] Penalties Imposed - The Chongqing Securities Regulatory Bureau ordered ST Tian Sheng to rectify its actions, issued a warning, and imposed a fine of 600,000 yuan [1] - Liu Qun received a warning and was fined 900,000 yuan, which included 300,000 yuan for being the directly responsible supervisor and 600,000 yuan for instructing illegal activities as the controlling shareholder [1] - Other individuals involved received varying fines and warnings, with penalties ranging from 120,000 yuan to 300,000 yuan [1] Market Bans - Liu Qun is subject to a lifetime ban from the securities market [1] - Li Hong faces an 8-year ban, while Wang Yonghong is banned for 5 years [1]